Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

ILMN - Illumina Inc


IEX Last Trade
131.4
-2.380   -1.811%

Share volume: 968,710
Last Updated: Fri 30 Aug 2024 09:59:57 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) : 0.87%

PREVIOUS CLOSE
CHG
CHG%

$133.78
-2.38
-1.78%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
10%
Profitability 1%
Dept financing 20%
Liquidity 75%
Performance 0%
Company vs Stock growth
vs
Performance
5 Days
0.01%
1 Month
7.27%
3 Months
37.67%
6 Months
-1.32%
1 Year
-16.22%
2 Year
-32.22%
Key data
Stock price
$131.40
P/E Ratio 
-6.88
DAY RANGE
$130.38 - $134.12
EPS 
-$18.81
52 WEEK RANGE
$84.06 - $158.48
52 WEEK CHANGE
-$0.17
MARKET CAP 
20.932 B
YIELD 
N/A
SHARES OUTSTANDING 
159.300 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
BETA 
1.37
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,112,218
AVERAGE 30 VOLUME 
$1,849,259
Company detail
CEO: Francis deSouza
Region: US
Website: https://www.illumina.com
Employees: 10,007
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services

at illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. these studies will help make the realization of personalized medicine possible. with such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. as a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. illumina’s innovative, array-based solutions for dna, rna, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.

Recent news